Evidence map›Paper›PMID 40649963›Full record

ArticleInternational journal of molecular sciences2025

Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells.

Natalie Luffman, Fereshteh Ahmadinejad, Ryan M Finnegan, Marissa Raymond, David A Gewirtz, Hisashi Harada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Natalie LuffmanDepartment of Human and Molecular Genetics, School of Medicine, Philips Institute for Oral Health Research, School of Dentistry, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Fereshteh AhmadinejadDepartment of Human and Molecular Genetics, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Ryan M FinneganDepartment of Microbiology and Immunology, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-4979-6906
Marissa RaymondDepartment of Pharmacology and Toxicology, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
David A GewirtzDepartment of Pharmacology and Toxicology, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0003-0437-4934
Hisashi HaradaPhilips Institute for Oral Health Research, School of Dentistry, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0001-5993-1289

Funding

A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cellsR01CA260819 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GEWIRTZ, DAVID A., HARADA, HISASHI · 2021 to 2025
$2.6M
NCI NIH HHS R01 CA260819
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) remains challenging to treat despite multimodal therapeutic approaches. Cisplatin treatment is effective and cost-efficient, although chemoresistance and disease recurrence limit its efficacy. Understanding the mechanisms of cisplatin resistance and the identification of compounds to target resistant tumor cells are critical for improving patient outcomes. We have demonstrated that cisplatin-induced senescent HN30 HNSCC cells can be eliminated by ABT-263 (navitoclax), a BCL-2/BCL-X

Indexed as

Aniline CompoundsAntineoplastic AgentsCisplatinDrug Resistance, NeoplasmHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckSulfonamidesApoptosisAzepinesCell Line, TumorCellular SenescenceHumansAniline CompoundsAntineoplastic AgentsAzepinesCisplatinnavitoclaxSulfonamidesABT-263BRD4chemoresistancecisplatinhead and neck cancerPROTACtherapy-induced senescence

Identifiers

PMID40649963
PMCPMC12250301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.